& Latchamsetty, K
The researchers also noted that the participants were predominantly White and female, which could have affected the results
55,56 Furthermore, a trial conducted in patients without T2DM indicated that liraglutide 3 mg daily provided benefits comparable to those of structured lifestyle changes in improving liver enzymes, insulin resistance, and weight, which are considered effective and fundamental measures for managing and improving MASLD/MASH
11 were in the final stages of clinical trials as of June 2024 [114] Among others, Hangzhou Jiuyuan Gene Engineering, The United Laboratories, CSPC Pharmaceutical Group, Huadong Medicine (which also holds a majority stake in Jiuyuan Gene [117] ) and Sihuan Pharmaceutical were all preparing generic offerings
The results of the study were evaluated at two key points: halfway through the trial at 24 weeks and again at the conclusion of the trial at 48 weeks